STAT+: Pharmalittle: Francis Collins to step down as NIH director; Research confirms decline in Pfizer vaccine protection against ‘breakthrough’ infection
Good morning, everyone, and how are you today? Gray skies are hovering over the Pharmalot…
Category: Pharmalot
STAT+: The Merck Covid-19 pill may be a game changer, but questions are already being raised about cost
Behind the unvarnished enthusiasm over an experimental Covid-19 pill, questions are emerging about the cost…
STAT+: Pharmalittle: J&J to seek emergency use of Covid-19 vaccine booster; Pfizer loses legal battle over Medicare co-pay programs
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pfizer loses a lawsuit alleging the U.S. illegally limits use of patient copay assistance programs
In a setback to the pharmaceutical industry, a federal judge ruled that programs Pfizer (PFE)…
STAT+: Three generic drug makers to pay $450 million to settle criminal price fixing charges
Three generic drug makers agreed to pay nearly $450 million to resolve civil allegations that…
For the first time, WHO committee recommends action on high-priced essential medicines
For the first time, a World Health Organization committee has recommended the global agency form…
STAT+: Pharmalittle: Merck’s Covid-19 pill reduced hospitalizations in a study; Dems start scaling back drug-pricing plans
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Appeals court rules FDA ‘arbitrarily and capriciously’ approved a rare disease drug
In a closely watched battle over regulatory decision-making, a federal appeals court ruled the U.S….
STAT+: Pharmalittle: House panel OKs bills to halt pharma practices that raise prices; Merck to buy Acceleron for $11.5 billion
Rise and shine, everyone, another busy day is on the way. This morning is getting…
STAT+: Pharmalittle: Run on ivermectin tablets leaves less for livestock; Pfizer Covid-19 shot for kids may not come until November
Hello, everyone, and welcome to the middle of the week. You made it this far,…
STAT+: As lawsuits mounted, Purdue cultivated conversations with a controversial addiction policy group
Over several months in 2017, a top Purdue Pharma executive and the head of the…
STAT+: Lilly cuts the wholesale price on some insulin products, but impact is likely to be limited
Eli Lilly (LLY) announced plans to lower the wholesale price of certain insulin products by…
.jpg)
STAT+: FDA tells drug makers to redo studies run by two contract research firms due to data integrity issues
In a rare move, the U.S. Food and Drug Administration has notified an untold number…
STAT+: Pharmalittle: Sanofi ends work on mRNA Covid-19 vaccine; Biogen seeks fast FDA approval of another Alzheimer’s drug
Top of the morning to you. And a fine one it is. Crystal clear blue…
STAT+: Inflation and rebates caused wholesale prices on medicines to drop in second quarter
Amid continued political pressure on the pharmaceutical industry, a new analysis finds brand-name drug makers…
STAT+: Pharmalittle: Moderate House Dems’ opposition to drug-pricing reforms shrinks; Glaxo goes on charm offensive
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: WHO adds Regeneron drug to recommended Covid-19 treatments, but criticizes its pricing
The World Health Organization added a Regeneron Pharmaceuticals medication to its list of recommended treatments…
STAT+: Pharmalittle: CDC director overrules panel and recommends Pfizer shot for at-risk workers; DOD watchdog faults military over pharma supply chain issues
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Defense Department watchdog criticizes oversight of military’s pharmaceutical supply chain
Amid mounting concerns over the U.S. pharmaceutical supply chain, a Department of Defense watchdog found…
STAT+: Pharmalittle: Pfizer CEO rallies employees to fight drug-price negotiations; Glaxo head pressured by another activist fund
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT+: Federal officials move closer to penalizing drug makers for failing to offer discounts to safety-net hospitals
Following a year of controversy, the Health Resources and Services Administration is taking steps to…
STAT+: Compound pharmacies win court battle over an FDA plan for monitoring shipments
A U.S. federal court judge has ruled that an effort by the Food and Drug…
STAT+: Pharmalittle: Biogen considers layoffs amid poor Alzheimer’s drug sales; House Dems plan showdown on drug-pricing vote
Hello, everyone, and how are you this fine, sunny morning? The middle of the week…
STAT+: Pharmalittle: J&J says its Covid-19 shot is more effective in two doses; India plans to resume Covid-19 vaccine exports
Top of the morning to you, and a fine one it is. Sunny skies and…
STAT+: U.S. lawmakers accuse patent office of weakening patent challenges and allowing drug prices to rise
A bipartisan group of lawmakers has accused the U.S. Patent & Trademark Office of “weakening”…
STAT+: Citing competitive concerns, European Commission seeks to intervene in Illumina’s $8 billion acquisition of Grail
In an unusual step, the European Commission plans to intervene in the recent merger between…
STAT+: Pharmalittle: Key Senate panel proposes expanded pharma pricing penalties; Biden will urge Covid-19 summit to help poor nations get vaccines
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Former Mylan IT exec pleads guilty to insider trading on earnings, drug approvals, and merger
A former Mylan information technology executive pleaded guilty to an insider trading scheme in which…
STAT+: U.K. government launches a new system to monitor clinical trial reporting
After a prolonged effort, the U.K. government is now tracking whether clinical trial sponsors are…
.jpg)
STAT+: Pharmalittle: FDA advisory panel to decide on Covid-19 boosters; Justice Dept. trustee appeals Purdue bankruptcy deal
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharmalittle: FDA scientists skeptical on boosters; moderate Democrats sink Pelosi’s drug pricing proposal
Good morning, all, I hope everyone is off to a good start. Ed is out…
STAT+: A ‘wonky’ congressional report will be a pharma talking point in the drug pricing debate
As lawmakers in Washington grapple with legislation to alter the upward trajectory of prescription drug…
STAT+: Safety-net hospitals take big markups on cancer drugs for commercially insured patients, study finds
Hospitals participating in a federal drug discount program marked up cancer medicines four times for…
STAT+: After a court let them off the hook, generic Zantac makers plan to seek legal expenses from consumers
A few months ago, a federal court judge dismissed all claims against more than a…
STAT+: Pharmalittle: Moderate Democrats threaten House drug-pricing bill; FDA reverses decision on reviewing ALS drug
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
STAT+: Pharmalittle: Purdue execs get their bonuses; Woodcock, two senators push patent office over pharma abuse
Top of the morning to you, and a fine one it is. The sun is…
STAT+: FDA commissioner, two senators raise concerns about patent abuse by pharmaceutical companies
In a bid to address the high cost of medicines, Food and Drug Administration Commissioner…
STAT+: Pharmalittle: International experts argue against Covid-19 boosters; centrist House Dems to release separate drug-pricing proposal
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Cancer drug indications remain on labels even after trials fail to confirm their benefits
One-third of the uses for cancer drugs granted speedy approvals remained on product labeling even…
STAT+: Biogen trials for Alzheimer’s drug excluded much of the targeted patient pool, study finds
A new analysis finds that the clinical trials conducted by Biogen (BIIB) for its controversial…
STAT+: Pharmalittle: Endo pays $50 million to settle opioid case; Senate mulls pegging drug prices to VA discounts
And so, another working week will soon draw to a close. Not a moment too…
STAT+: For the first time, the FDA warns a trial investigator for failing to report study results
In a little noticed warning, the Food and Drug Administration threatened to fine the principal…
STAT+: Pharmalittle: Biden drug-pricing plan backs Medicare negotiations; Moderna tests combined Covid-19 booster and flu shot
Good morning, everyone, and nice to see you again. We have finally returned from an…
STAT+: Pharmalittle: Sanofi will acquire Kadmon Pharma for $1.9 billion; Theranos founder Elizabeth Holmes goes on trial
Good morning. Happy Wednesday. This is Kate Sheridan, filling in for Ed Silverman this morning…
STAT+: Pharmalittle: CEPI warns of hurdle to new Covid-19 vaccines; reading tea leaves on booster side effects
G’morning to ya! Nicholas St. Fleur here to fill in for Ed following this Labor…
STAT+: Pharmalittle: Lawmakers ramp up probe of FDA approval of Biogen drug; EU to return J&J Covid-19 shots to Africa
And so, another working week will soon draw to a close. Not a moment too…
The Purdue bankruptcy plan was approved. Will it get derailed by appeals?
A bankruptcy court has approved a settlement to funnel billions of dollars to pay for…
STAT+: Older job seekers claim that Lilly favors millennials when it comes to hiring sales reps
In order to win the attention of physicians, Eli Lilly (LLY) has deliberately sought to…
STAT+: Pharmalittle: Purdue bankruptcy plan is approved but appeals expected; FDA warns about safety risks with arthritis drugs
Top of the morning to you. And a fine one it is. Lots of sunshine…
Judge approves Purdue’s controversial bankruptcy plan, paving the way for immunity for Sacklers
After two years of contentious bargaining, a U.S. bankruptcy court judge on Wednesday approved a…